Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...
A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Nanyang Technological University, Singapore (NTU Singapore) is working with China’s Southern University of Science and ...
University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...
A new inhaled therapy targets ANGPTL4 to reduce lung inflammation, fluid buildup, and scarring after infections. Preclinical ...
Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results